India’s Bharat Biotech submits data on COVID-19 drug trial in children
Excerpt from the Press Release:
BENGALURU, Oct 6 (Reuters) – Bharat Biotech said on Wednesday it had submitted data from its COVID-19 vaccine trial in children aged 2 to 18 years to India’s drug regulator, becoming the country’s first company to have tested its shot in very young children.
The South Asian country is turning its focus towards vaccinating children against the coronavirus, having already administered more than 920 million doses to adults among its population of nearly 1.4 billion.
India’s drug regulator last month allowed vaccine maker Serum Institute to enroll kids aged 7 to 11 years for its trial of U.S. drugmaker Novavax’s (NVAX.O) COVID-19 vaccine. read more
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?